What the trial was testing
The trial enrolled 165 patients with vasculitis. The study was sponsored by Poitiers University Hospital and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
Researchers followed patients through treatment and into recovery, tracking the outcomes that mattered most for the disease being studied.
What the results showed
Ultrasound correctly identified 54% of giant cell arteritis cases without needing a biopsy.
Annals of internal medicine · 2024 · NCT02703922
These findings — that ultrasound correctly found giant cell arteritis without biopsy — were published in the Annals of internal medicine and represent the headline result of the study.
Researchers tracked outcomes across 165 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with vasculitis, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Ultrasound is already widely available and used for many conditions. This study suggests it can help diagnose giant cell arteritis faster, potentially avoiding biopsies. If you have symptoms like temple pain or vision changes, ask your doctor whether ultrasound might be appropriate for you.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open vasculitis trials
Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)
This study is a prospective, open-labelled, randomized, controlled, single-center clinical trial. The aim of this study is to compare the remission rate of patients treated with Telitacicept combined with azathioprine and azathioprine alone in remission-maintenance treatment of AAV.
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
The main purpose of study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of benralizumab.